Table 4 Treatment Discontinuation Rates
Parameter | Value | Data Source | |||
|---|---|---|---|---|---|
Annual All-Cause Discontinuation Rates | |||||
Olanzapine | 54.0% | Â | |||
Risperidone | 63.0% | Lieberman et al., 2005 [23] | |||
Quetiapine | 76.0% | Â | |||
Ziprasidone | 74.0% | Â | |||
Aripiprazole | 61.0% | Fleischhacker et al., 2008 [68] | |||
Annual Discontinuation Rates by Reason | |||||
| Â | Lack of Efficacy | Intolerability | Patient Decision | Other | Â |
Olanzapine | 13% | 16% | 20% | 5% | Â |
Risperidone | 22% | 10% | 22% | 9% | Lieberman et al., 2005 [23] |
Quetiapine | 27% | 14% | 29% | 6% | Â |
Ziprasidone | 25% | 13% | 30% | 6% | Â |
Aripiprazole | 15% | 18% | 23% | 5% | Fleischhacker et al., 2008 [68] |